 Enzyme Inhibitors
"Enzyme Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction.
| Descriptor ID |
D004791
|
| MeSH Number(s) |
D27.505.519.389
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Enzyme Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Enzyme Inhibitors".
This graph shows the total number of publications written about "Enzyme Inhibitors" by people in this website by year, and whether "Enzyme Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 5 | 12 | 17 | | 1997 | 5 | 16 | 21 | | 1998 | 4 | 9 | 13 | | 1999 | 9 | 15 | 24 | | 2000 | 7 | 21 | 28 | | 2001 | 9 | 26 | 35 | | 2002 | 9 | 43 | 52 | | 2003 | 10 | 25 | 35 | | 2004 | 5 | 29 | 34 | | 2005 | 9 | 16 | 25 | | 2006 | 10 | 19 | 29 | | 2007 | 16 | 15 | 31 | | 2008 | 9 | 22 | 31 | | 2009 | 5 | 19 | 24 | | 2010 | 8 | 11 | 19 | | 2011 | 13 | 13 | 26 | | 2012 | 10 | 21 | 31 | | 2013 | 5 | 21 | 26 | | 2014 | 11 | 15 | 26 | | 2015 | 8 | 10 | 18 | | 2016 | 9 | 7 | 16 | | 2017 | 6 | 3 | 9 | | 2018 | 10 | 5 | 15 | | 2019 | 3 | 7 | 10 | | 2020 | 7 | 2 | 9 | | 2021 | 7 | 3 | 10 | | 2022 | 0 | 5 | 5 | | 2023 | 0 | 2 | 2 | | 2024 | 2 | 4 | 6 | | 2025 | 6 | 0 | 6 | | 2026 | 2 | 1 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Enzyme Inhibitors" by people in Profiles.
-
Riedel C, Rahkola J, Reichlen M, Ries H, Ericksen SS, Voskuil M, Gitter A, Wlodarchak N. Identification and characterization of inhibitors of the tuberculosis phosphatase PstP. J Biol Chem. 2026 Apr; 302(4):111316.
-
Meena S, Fatima F, Qais FA, Ramachandran S. Computational screening of natural plant and marine compounds as potential inhibitors of Mycobacterium tuberculosis dihydrodipicolinate synthase. Comput Biol Chem. 2026 Jun; 122:108936.
-
Lee ES, Tommer ER, Rothman PB, Middleton SV, Youmans DT, Cech TR. Single-molecule tracking of DNMT1 in living cells reveals its cell cycle dynamics and its redistribution upon drug treatment. Nucleic Acids Res. 2026 Feb 05; 54(4).
-
Bellver-Sanchis A, Valle-Garcia D, Barbaraci C, Romero-Becerra F, Singh RK, Jarne-Ferrer J, Vasilopoulou F, Irisarri A, Martínez-Fernández C, Fafián-Labora JA, Arufe MC, Wüst C, Castellanos A, Soto D, Casals N, Fadó R, Pocock JM, Navarro G, Val C, Brea J, Loza MI, Lleó A, Fortea J, Alcolea D, Perez-Bosque A, Miró L, Pérez B, Rashid S, Ali M, Saqib M, Lí Carbó M, Guerrero A, Vázquez S, Choudhary BS, Dai S, Escolano C, Franco R, Pallàs M, Griñán-Ferré C. First-in-class SAM-competitive G9a inhibitor FLAV-27 as a disease-modifying therapy for Alzheimer disease. Mol Ther. 2026 Apr 01; 34(4):2372-2407.
-
Claus LW, Auten ME, Saseen JJ, Billups SJ. Guideline adherence of xanthine oxidase inhibitor utilization to treat gout in primary care. J Manag Care Spec Pharm. 2025 Sep; 31(9):922-927.
-
Muthu Ramalingam B, Sears JD, Talbot KM, Su YN, Houliston S, Hossain MA, Davis-Gilbert ZW, Zhao C, Oh HJ, Brown PJ, Sanders MK, Moorman SR, Ojha D, Burdick JE, Law I, Morales NL, Martinez SA, Loppnau P, Garcia Perez J, Drobish AM, Morrison TE, Streblow ZJ, Streblow DN, Arrowsmith CH, Vargason A, Couñago RM, Halabelian L, Arnold JJ, Cameron CE, Moorman NJ, Heise MT, Willson TM. Identification of Direct-Acting nsP2 Helicase Inhibitors with Antialphaviral Activity. J Med Chem. 2025 Jul 24; 68(14):14514-14536.
-
Nesbitt NM, Araldi GL, Pennacchia L, Marchenko N, Assar Z, Muzzarelli KM, Thekke Veedu RR, Medel-Lacruz B, Lee E, Eisenmesser EZ, Kreitler DF, Bahou WF. Small molecule BLVRB redox inhibitor promotes megakaryocytopoiesis and stress thrombopoiesis in vivo. Nat Commun. 2025 Apr 11; 16(1):3480.
-
Andrews J, Paganoni S, Macklin EA, Chibnik LB, Quintana M, Saville BR, Detry MA, Vestrucci M, Marion J, McGlothlin A, Young E, Chase M, Pothier L, Harkey B, Yu H, Sherman A, Shefner J, Hall M, Kittle G, Connolly MR, Berry JD, D'Agostino D, Tustison E, Giacomelli E, Scirocco E, Alameda G, Locatelli E, Ho D, Quick A, Heitzman D, Ajroud-Driss S, Appel SH, Shroff S, Katz J, Felice K, Maragakis NJ, Simmons Z, Goutman SA, Olney N, Miller T, Fernandes JA, Ilieva H, Jawdat O, Weiss MD, Foster L, Vu T, Ladha S, Owegi MA, Newman DS, Arcila-Londono X, Jackson CE, Swenson A, Heiman-Patterson T, Caress J, Fee D, Peltier A, Lewis R, Rosenfeld J, Walk D, Johnson K, Elliott M, Kasarskis EJ, Rutkove S, McIlduff CE, Bedlack R, Elman L, Goyal NA, Rezania K, Twydell P, Benatar M, Glass J, Cohen JA, Jones V, Zilliox L, Wymer JP, Beydoun SR, Shah J, Pattee GL, Martinez-Thompson J, Nayar S, Granit V, Donohue M, Grossman K, Campbell DJ, Qureshi IA, Cudkowicz ME, Babu S. Verdiperstat in Amyotrophic Lateral Sclerosis: Results From the Randomized HEALEY ALS Platform Trial. JAMA Neurol. 2025 04; 82(4):333-343.
-
Murphy CS, Fairfield H, DeMambro VE, Fadel S, Gartner CA, Karam M, Potts C, Rodriguez P, Qiang YW, Hamidi H, Guan X, Vary CPH, Reagan MR. Inhibition of acyl-CoA synthetase long-chain isozymes decreases multiple myeloma cell proliferation and causes mitochondrial dysfunction. Mol Oncol. 2025 Jun; 19(6):1687-1706.
-
Garcia VP, Stockelman KA, Levy MV, Fandl HK, Goulding A, Hijmans JG, Ruzzene ST, Berry AR, Greiner JJ, DeSouza CA. Microvesicles Derived from Nitric Oxide Synthase-Inhibited Endothelial Cells Promote Cell Dysfunction. J Vasc Res. 2025; 62(1):10-21.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|